Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1994-05-17
1995-06-20
Henley, III, Raymond
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
A61K 3141
Patent
active
054261147
ABSTRACT:
The present invention pertains to antagonists of excitatory amino acid receptors, their method or preparation as well as compositions pertaining to them, which have the general formula: ##STR1## wherein R1 and R2 are selected from the group of hydrogen and C1 to C6 lower alkyl; the stereoisomers being in their resolved or racemic form; n and m are independently 0, 1, 2, or 3; and pharmaceutically acceptable salts thereof.
REFERENCES:
patent: 4657899 (1987-04-01), Rzeszotarski et al.
patent: 4761405 (1988-08-01), Rzeszotarski et al.
patent: 4822780 (1989-04-01), Tsuda et al.
patent: 4918064 (1990-04-01), Cordi et al.
patent: 5049555 (1991-09-01), Rzeszotarski et al.
patent: 5331001 (1994-07-01), Hamilton
Watkins et al., "Excitatory Amino Acid Transmitters," Amer. Rev. Pharmacol. Toxicol. (1981), vol. 21, pp. 165-204.
Schwarcz et al., "Quinolinic Acid: An Endogenous Metabolite that Produces Axon-Sparing Lesions in Rat Brain," Science, Jan. 1983, vol. 219, pp. 316-318.
Simon et al., "Blockade of N-Methyl-D-Aspartate Receptors May Protect Against Ischemic Damage in the Brain," Science, vol. 226, pp. 850-852 (1983).
Foster et al., "Acidic Amino Acid Binding Sites in Mammalian Neuronal Membranes: Their Characteristics and Relationship to Synaptic Receptors," Brain Research Reviews, vol. 7, (1984), pp. 103-164.
Schoepp et al., "Pharmacological and Functional Characteristics of Metabotropic Excitatory Amino Acid Receptors," Tr. Pharmacol. Sci., Special Report (1991), pp. 74-81.
Faden et al., "Effects of Competitive and Non.gtoreq.Competitive NMDA Receptor Antagonists in Spinal Cord Injury," European Journal of Pharmacology, vol. 175 (1990), pp. 165-174.
Frandsen et al., "Direct Evidence that Excitotoxicity in Cultured Neurons is Mediated via N-Methyl-D-Aspartate (NMDA) as well as Non-NMDA Receptors," Journal of Neuro-Chemistry, vol. 53, No. 1, 1989, pp. 297-299.
Sheardown et al., "2,3-Dihydroxy-6-nitro-7-sulfamoyl-benzo(F)quinoxaline: A Neuroprotectant for Cerebral Ischemia," Science, vol. 247, Feb. 1990, p. 571.
Costa, "Allosteric Modulatory Centers of Transmitter Amino Acid Receptors," Neuropsychopharmacology, vol. 2, No. 3, (1989), pp. 167-174.
Matoba et al., "Structural Modification of Bioactive Compounds. II. Syntheses of Aminophosphonoic Acid," Chem. Pharm. Bulletin, vol. 32 (1984), pp. 3918-3925.
Lodge et al., [Eds.], "The Pharmacology of Excitatory Amino Acids," Elsevier Trends Journal (1991).
Guilford Pharmaceuticals Inc.
Henley III Raymond
Nath Gary M.
LandOfFree
.omega.-[2-(tetrazolylalkyl)cyclohexyl]-2-aminoalkanoic acids as does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with .omega.-[2-(tetrazolylalkyl)cyclohexyl]-2-aminoalkanoic acids as, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and .omega.-[2-(tetrazolylalkyl)cyclohexyl]-2-aminoalkanoic acids as will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1844317